TUMS antacid tablets recalled due to glass mineral wool contamination
GlaxoSmithKline is recalling TUMS Antacid tablets (Lot HB2G) due to glass mineral wool contamination. Affected product was distributed nationwide.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is a Class II FDA recall for glass mineral wool contamination. The hazard presents a risk of physical harm if contaminated tablets are ingested, but no illnesses or injuries are documented, fitting the High severity criterion for risk-of-harm products where injury has not yet been reported.
Plain-English summary
GlaxoSmithKline Consumer Healthcare Holdings LLC is recalling TUMS Antacid tablets (Calcium Carbonate USP 1000 mg, Peppermint flavor, 72-count bottles) due to the presence of glass mineral wool, a foreign material.
The affected product is Lot HB2G with expiration date August 31, 2027, identified by NDC 0135-0228-06 and UPC 307660745853. The product was distributed nationwide within the United States.
Consumers who have purchased this product from the affected lot should discontinue use due to the contamination risk.
The recalled product
- Product
- TUMS (CALCIUM CARBONATE)
- Brand
- TUMS
- Manufacturer
- GlaxoSmithKline Consumer Healthcare Holdings LLC
- Category
- Drug — Antacid
- Hazard
- glass-contamination
- foreign-substance
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot#: HB2G
- Exp. Date 8/31/2027
UPCs (1)
- 307660745853
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · TUMS
- HighFDA Recalls TUMS Antacid Tablets for Glass Mineral Wool Contamination
FDA (Drugs) · 2023-11-08
- HighTUMS Antacid Recalled for Glass Mineral Wool Contamination
FDA (Drugs) · 2023-11-08
- HighTUMS Antacid Recalled for Glass Mineral Wool Contamination
FDA (Drugs) · 2023-11-08
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModeratePovi-One Povidone-Iodine 10% Topical Drug Recall for Sub Potency
FDA (Drugs) · 2026-07-01
- ModerateSensipar cinacalcet hydrochloride tablets recalled for CGMP deviations
FDA (Drugs) · 2026-07-01
- ModerateSensipar Cinacalcet Tablets Recalled Due to CGMP Deviations
FDA (Drugs) · 2026-07-01
- ModerateSensipar (Cinacalcet Hydrochloride) Tablets Recalled for CGMP Deviations
FDA (Drugs) · 2026-07-01